NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research

        • Research Overview
        • Clinical Research Facility
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient & Public Involvement
    • Getting involved with research
    • Welcome Guide
    • View and register for involvement opportunities
    • Patient & Public Groups
    • Patient and Public Involvement Advisory Group
    • Diversity in Research Group
    • Case Studies
    • Patient and Public Involvement and Engagement (PPIE) Strategy
    • PPIE News
    • PPI Researcher Guidance
    • Researchers: Post a PPIE opportunity
    • Public events
    • Patient & Public Involvement events
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > Common heart medication does not increase risk of COVID-19 hospitalisation

Common heart medication does not increase risk of COVID-19 hospitalisation

10 August 2020 · Listed under Cardiovascular Medicine, COVID-19, Digital Health from Hospital to Home, Translational Data Science

A study by Oxford researchers, supported by the NIHR Oxford Biomedical Research Centre (BRC), found that ACE inhibitors and ARBs – both common treatments for high blood pressure and heart failure – are not generally linked to an increased risk of severe COVID-19 disease or an increased likelihood of being admitted to intensive care.

Photo by Christine Sandu on Unsplash

However, the researchers did find higher risk of severe COVID-19 disease for some BAME groups, especially Black African patients taking ACE inhibitors. The study was published as an open access paper in the BMJ Heart journal.

Angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) are common heart medications to treat heart failure and high blood pressure, and are often prescribed following a heart attack. 

Prof Julia Hippisley-Cox of the Nuffield Department of Primary Care Health Sciences and Prof Peter Watkinson, the Oxford BRC’s Joint Theme Lead for Technology and Digital Health led the study.

Prof Watkinson said: “There had been some uncertainty about the relationship between these common heart medications and COVID-19 disease. We set out to find out if patients prescribed these drugs had altered risks of contracting severe COVID-19 disease and of being admitted to ICU.”

This large, population-based study matched the records of 1,205 UK general practices contributing to the QResearch database with data from Public Health England and from the Intensive Care National Audit and Research Centre (ICNARC).

Prof Hippisley-Cox said: “We examined the drug histories of around 20% of all patients in England who tested positive for coronavirus, to see if there was an independent association between ACE inhibitor or ARB drug prescription and severe COVID-19 disease susceptibility and progression.

“We found overall ACE inhibitors and ARBs were associated with a reduced risk of severe COVID-19 disease, but not associated with the risk of needing admission to an Intensive Care Unit. However, our findings varied by ethnicity. For Black African groups, taking ACE inhibitors was associated with an increased risk of severe COVID-19 disease.”

She added: “This variation between different ethnic groups raises the possibility of specific effects of these drugs on susceptibility to COVID-19 among certain groups and on the severity of the disease, and this deserves further study.”

← Oxford University and ZOE partner on COVID-19 treatment trials
Paper outlines management of post-acute COVID-19 in primary care →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2023 NIHR Oxford Biomedical Research Centre